BioSpace News Archive

Global health service company Cigna has named Robert Pettigrew president of its Medicare Advantage plans in Alabama, Mississippi and Northwest Florida.

Sector financing reached $19.9B in 2020, doubling from the previous year; 2021 is likely to be a record year for the number of regulatory decisions on new regenerative medicine products

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will participate in the Oppenheimer 31st Annual Healthcare Conference

Dr. Borjigin is a faculty member of the Center for Consciousness Science at the University of Michigan Medical School and is an Associate Professor in the Department of Molecular and Integrative Physiology and the Department of Neurology at the University of Michigan.

The funding application is entitled “A novel rapid, liquid biopsy early-stage lung cancer diagnostic test”. The grant was for $150,000.

ReddyPort, a medical technology company focused on bringing non-invasive ventilation (NIV) products into market, announced today the launch of ReddyPort™ Microphone and Controller, a first-of-its-kind device that includes a single-patient use microphone which integrates with ReddyPort™ Elbow,

Immune Biosolutions, an innovative biotechnology company, receives $13.44M from the Government of Canada’s Strategic Innovation Fund (SIF) to develop its promising immunotherapy whose antibodies have the potential to neutralize and eliminate COVID-19 and its variants.

STRATA Skin Sciences, Inc. (“STRATA”) (NASDAQ: SSKN), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that the company will participate in the upcoming Lytham Partners Spring 2021 Investor Conference.

- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company today announced the treatment of the first subject in the First-in-Human Phase I clinical trial

Amyris, Inc., a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands and a top supplier of sustainable and natural ingredients, announced that it has signed a memorandum of understanding for a partnership with Minerva Foods of Brazil to develop molecules for the sustainable production and distribution of animal protein.